Newsletter Subscribe
Enter your email address below and subscribe to our newsletter
Enter your email address below and subscribe to our newsletter

Outlook Therapeutics announced the submission of its Marketing Authorisation Application (MAA) to the United Kingdom’s Medicines and Healthcare products Regulatory Agency (MHRA) in a press release. The MAA is for bevacizumab gamma (ONS-5010/LYTENAVA), its investigational formulation of bevacizumab for the…

Rezolute announced promising topline results from its Phase 2 clinical study of RZ402. This study targeted patients with diabetic macular edema (DME) who were either naïve to or had limited exposure to anti-vascular endothelial growth factor (anti-VEGF) injections. Monumental Results…

New World Medical announced a significant milestone with the receipt of 510(k) indication expansion from the U.S. Food and Drug Administration (FDA) for KDB (Kahook Dual Blade) GLIDE. This clearance allows for the reduction of intraocular pressure (IOP) in adult…

A recent study published in JAMA Ophthalmology reveals a troubling correlation between residential measures of inequity and the prevalence of vision difficulty and blindness (VDB) among individuals. Led by Patrice M. Hicks, Ph.D., M.P.H., from the University of Michigan in…

HealthyCell has launched its latest product, Eye Health, a novel ultra-absorbable gel supplement designed to enhance and maintain eye health. This new offering comes at a time when preserving vision is increasingly important due to an aging population and the…
Neuro-ophthalmology in the United Kingdom: providing a sustainable, safe and high-quality service for the future | Eye Nature Source: Author: | Date: 2024-05-22 07:00:00 Source: Author: | Date: 2024-05-22 07:00:00

Clearside Biomedical has taken a significant step forward in the field of ophthalmology by publishing new guidelines for suprachoroidal space (SCS) injection, a technique used to deliver medication directly to the back of the eye. These guidelines have been featured…

Innovent Biologics announced that its New Drug Application (NDA) for their recombinant anti-insulin-like growth factor 1 receptor (IGF-1R) antibody, IBI311, has been accepted and granted priority review designation by the Center for Drug Evaluation (CDE) of the China National Drug…

Biocon Biologics today announced that the US FDA has approved the Company’s first-to-file application for Yesafili™ (aflibercept-jbvf), an interchangeable biosimilar aflibercept. Indications and Uses of YESAFILI YESAFILI, a vascular endothelial growth factor (VEGF) inhibitor used to treat several ophthalmology conditions,…

In a study published in the journal JAMA Ophthalmology, researchers at Tokyo Medical and Dental University (TMDU) in Japan have successfully pioneered a new optical coherence tomography (OCT) technique. This innovative method, known as polarization-sensitive OCT (PS-OCT), provides unprecedented insights…